Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions remain.

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health ...